Tumor suppression effect of ultrasound-sensitive nanoparticles with focused ultrasound in a pancreas cancer xenograft model

• Published in: European radiology experimental 2024-03, Vol.8 (1), p.39-39, Article 39
• Main Authors: Kim, Soojin, Lee, Jae Young, Park, Eun-Joo, Ahn, Yun Deok, Cheon, Yuri, Sim, Wonchul, Lee, Hak Jong
• Format: Article
• Language: English
• Subjects: Chemotherapy; Diagnostic Radiology; Doxorubicin; Heterografts; Imaging; Internal Medicine; Interventional Radiology; Liposomal doxorubicin; Medicine; Medicine & Public Health; Neuroradiology; Original; Original Article; Pancreatic cancer; Pancreatic neoplasms; Radiology; Ultrasonic imaging; Ultrasonic therapy; Ultrasound
• ISSN: 2509-9280; 2509-9280
• DOI: 10.1186/s41747-024-00436-2

Background We investigated the tumor suppression effect of an ultrasound-sensitive doxorubicin-loaded liposome-based nanoparticle, IMP301, to enhance the synergistic effect with focused ultrasound (FUS) in an animal model of pancreatic cancer. Methods Thirty nude mice with xenografts of PANC-1 human pancreatic cancer cells were randomly and prospectively allocated to 6 different groups (5 per group) each for Study-1 (dose–response test) and Study-2 (synergistic effect test). Study-1 consisted of control, gemcitabine, Doxil with FUS, and three different doses of IMP301 (2, 4, 6 mg/kg) with FUS groups. Study-2 consisted of control, FUS only, gemcitabine, Doxil with FUS, and IMP301 (4 mg/kg) with or without FUS groups. Differences in tumor volume and growth rate were evaluated by one-way ANOVA and Student–Newman–Keuls test. Results In Study-1, 4 mg/kg or greater IMP301 with FUS groups showed lower tumor growth rates of 14 ± 4 mm 3 /day (mean ± standard deviation) or less, compared to the control, gemcitabine, and Doxil with FUS groups with rates exceeding 28 ± 5 ( p